Abalone Bio is pioneering the development of target-activating antibodies, particularly focusing on challenging disease targets such as G-protein coupled receptors (GPCRs). Their innovative approach addresses significant limitations in current drug discovery methods, which often fail to deliver effective therapeutics for key targets. The company has developed a platform known as Functional Antibody Selection Technology (FAST), which allows for the rapid creation and evaluation of millions of antibody variants. This platform measures the functional activity of antibodies rather than just their binding capabilities, enabling the identification of rare activators that can specifically modulate GPCRs and other complex membrane proteins.

The FAST platform utilizes engineered yeast cells to conduct high-throughput screening, linking cell survival to the functional activity of antibodies. This method not only accelerates the discovery of effective antibody activators but also generates extensive datasets that can be leveraged for AI-guided antibody design. By focusing on the specific activation of targets, Abalone Bio aims to enhance therapeutic efficacy while minimizing side effects, thereby addressing the unmet medical needs of millions of patients. Their work has already led to the successful discovery of activators for two GPCRs, showcasing the potential of their technology in transforming antibody drug development.

United States

The remarkable specificity and safety of antibody drugs have been limited to blocking inactivators for the largest class of drug targets. Abalone Bio develops antibody drugs that activate, enabling us to turn on previously inaccessible biological activities like anti-cancer or anti-inflammatory actions.

Abalone Bio

Company Details